{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:07:33Z","timestamp":1760058453431,"version":"build-2065373602"},"reference-count":30,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Hepatitis B virus (HBV) is a virus that can cause chronic hepatitis B (CHB) in humans, leading to cirrhosis and hepatocellular carcinoma (HCC). In this study, we aimed to investigate the relationships between early ALT normalization (at 12 months), the virologic response in CHB patients, and the risk of HCC development. Methods: Data from a retrospective cohort study involving 616 chronic hepatitis B patients were used. The effects of ALT normalization and virologic response on the risk of developing HCC at 12 months of treatment were analyzed. Results: During a median treatment duration of 70.9 months, 36 (5.8%) HCC cases were detected in the total patient population. ALT normalization was detected in 68.83% of patients at 12 months of treatment. The rate of HCC in the group with early ALT normalization was lower than that in the group without ALT normalization, but this difference was not statistically significant (5% vs. 7.8%, p = 0.161). At the end of 12 months of treatment, virologic response was detected in 80.68% of the patients. The rate of patients developing HCC was significantly lower in the virologic response group (4.8% vs. 10.1%, p = 0.028). However, the risk of developing HCC was also significantly higher in the virologically unresponsive group, according to the virologic response at 12 months (p = 0.034). Conclusions: According to the results of this study, achieving virologic response at the end of 12 months in genotype D CHB patients treated with nucleos(t)ide analogs (NAs) reduces the risk of developing HCC.<\/jats:p>","DOI":"10.3390\/jcm14082618","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T05:38:26Z","timestamp":1744349906000},"page":"2618","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Virologic Response at 12 Months Predicts Lower Hepatocellular Carcinoma Risk in Genotype D Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogues"],"prefix":"10.3390","volume":"14","author":[{"given":"Oguzhan","family":"Ozturk","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Biruni University, G\u00fcltepe, Halkal\u0131 Street Number: 99, Istanbul 34295, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatih","family":"Guzelbulut","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Umraniye Training and Research Hospital, University of Health Sciences, Elmalikent, Adem Yavuz Street No:1, Istanbul 34764, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamil","family":"Ozdil","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine, Biruni University, G\u00fcltepe, Halkal\u0131 Street Number: 99, Istanbul 34295, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7827-8115","authenticated-orcid":false,"given":"Huseyin","family":"Aykut","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Umraniye Training and Research Hospital, University of Health Sciences, Elmalikent, Adem Yavuz Street No:1, Istanbul 34764, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2157-0304","authenticated-orcid":false,"given":"Gupse","family":"Adal\u0131","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Umraniye Training and Research Hospital, University of Health Sciences, Elmalikent, Adem Yavuz Street No:1, Istanbul 34764, T\u00fcrkiye"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"18035","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis B virus infection","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_2","unstructured":"World Health Organization (2022, March 12). Hepatitis B. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1111\/j.1572-0241.2000.03373.x","article-title":"Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients","volume":"95","author":"Chan","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2018.05.009","article-title":"Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B","volume":"69","author":"Wong","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"406","DOI":"10.14309\/ajg.0000000000000490","article-title":"Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated with Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B","volume":"115","author":"Choi","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1053\/j.gastro.2011.06.036","article-title":"Changes in Serum Levels of HBV DNA and Alanine Aminotransferase Determine Risk for Hepatocellular Carcinoma","volume":"141","author":"Chen","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.3748\/wjg.v20.i18.5427","article-title":"Hepatitis B virus genotypes: Global distribution and clinical importance","volume":"20","author":"Sunbul","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_9","first-page":"183","article-title":"Determination of hepatitis B genotypes in patients with chronic hepatitis B virus infection in Turkey","volume":"16","author":"Duman","year":"2005","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2009). EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J. Hepatol., 50, 227\u2013242.","DOI":"10.1016\/j.jhep.2008.10.001"},{"key":"ref_12","unstructured":"European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_13","unstructured":"WHO (2000). Obesity: Preventing and Managing the Global Epidemic, WHO. Report of a WHO Consultation. WHO Technical Report Series 894."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.2337\/dci23-0036","article-title":"Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus","volume":"46","author":"Sacks","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.cgh.2009.05.025","article-title":"Surrogate end points and long-term outcome in patients with chronic hepatitis B","volume":"7","author":"Wong","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Kim, S., Lee, Y., Bang, S.M., Bak, H., Yim, S.Y., Lee, Y.S., Yoo, Y.J., Jung, Y.K., Kim, J.H., and Seo, Y.S. (2021). Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients. J. Clin. Med., 10.","DOI":"10.3390\/jcm10091840"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.3748\/wjg.15.5761","article-title":"Clinical relevance and public health significance of hepatitis B virus genomic variations","volume":"15","author":"Cao","year":"2009","journal-title":"World J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"ofac492.1079","DOI":"10.1093\/ofid\/ofac492.1079","article-title":"1248. Relationship Between ALT and New HBV Biomarkers in HBV\/HIV Coinfected Persons Started on Antiviral Therapy","volume":"9","author":"Rouster","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Inoue, J., Kobayashi, T., Akahane, T., Kimura, O., Sato, K., Ninomiya, M., Iwata, T., Takai, S., Kisara, N., and Sato, T. (2022). Non-Achievement of Alanine Aminotransferase Normalization Associated with the Risk of Hepatocellular Carcinoma during Nucleos(t)ide Analogue Therapies: A Multicenter Retrospective Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092354"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100350","DOI":"10.1016\/j.jhepr.2021.100350","article-title":"Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B","volume":"3","author":"Choi","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_22","first-page":"914","article-title":"Features of the metabolic syndrome are associated with lack of serum ALT normalization during therapy for chronic hepatitis B","volume":"64","author":"Fung","year":"2016","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: Trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Pandyarajan, V., Govalan, R., and Yang, J.D. (2021). Risk Factors and Biomarkers for Chronic Hepatitis B Associated Hepatocellular Carcinoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22020479"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1080\/17474124.2021.1980385","article-title":"Virologic response maintenance and hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir","volume":"15","author":"Wang","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s10620-020-06375-3","article-title":"Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir","volume":"66","author":"Shin","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/jgh.16357","article-title":"Risk factors of low-level viremia in chronic hepatitis B patients receiving Entecavir monotherapy: A retrospective cohort study","volume":"39","author":"Chen","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1097\/HEP.0000000000000037","article-title":"Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis","volume":"77","author":"Huang","year":"2023","journal-title":"Hepatology"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2618\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:12:40Z","timestamp":1760029960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/8\/2618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["jcm14082618"],"URL":"https:\/\/doi.org\/10.3390\/jcm14082618","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,4,11]]}}}